RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Short Interest Down 73.1% in April

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 22,000 shares, a decrease of 73.1% from the March 31st total of 81,700 shares. Based on an average trading volume of 7,859,600 shares, the short-interest ratio is presently 0.0 days.

RespireRx Pharmaceuticals Price Performance

Shares of RSPI remained flat at $0.00 during mid-day trading on Thursday. 420,000 shares of the stock traded hands, compared to its average volume of 12,124,260. RespireRx Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.02. The stock has a market cap of $673,973.34, a PE ratio of -0.04 and a beta of 0.49.

About RespireRx Pharmaceuticals

RespireRx Pharmaceuticals Inc engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.